New drug aims to stop Post-Surgery breathing danger
NCT ID NCT06137638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether the drug ENA-001 can prevent respiratory depression (dangerously slow or shallow breathing) after major surgery under general anesthesia. About 200 adults having elective surgery will receive either ENA-001 or a placebo as an IV drip. The study is double-blind, meaning neither patients nor doctors know who gets the real drug. The main goal is to see if ENA-001 improves carbon dioxide levels in the blood, a key sign of healthy breathing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENA-001 (given as an IV infusion)
What this could lead to
If it works, this could lead to a new way to prevent dangerous shallow breathing after major surgery, reducing complications and ICU stays.
What could go wrong
This is an early Phase 2 trial with only 200 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••